KEAP1 and neoplasm: Consistent with this model, patients with KEAP1 mutant tumours, which exhibit constitutive activation of NRF2 and therefore cannot benefit from G12Ci-induced NRF2 activity, have a poor prognosis in response to Sotorasib or Adagrasib [49, 56].